Paquette D, Snider J, Bouchard F, Olivotto I, Bryant H, Decker K, Doyle G
Centre for Chronic Disease Prevention and Control (Formerly the Laboratory Centre for Disease Control), Health Canada, Ottawa, Ont.
CMAJ. 2000 Oct 31;163(9):1133-8.
The results of randomized trials show that breast cancer screening by mammography reduces breast cancer mortality by up to 40% in women aged 50-69 years. Because of these results, by 1998, 22 countries, including Canada, had established population-based organized screening programs. This paper presents the results of screening mammography in 1996 for 7 provincially organized breast cancer screening programs in Canada.
Analyses of interim performance indicators for screening mammography have been calculated from data submitted to the Canadian Breast Cancer Screening database. The data set consisted of data from 7 provincial programs and was limited to mammographic screens for women aged 50-69 years (n = 203,303). Screening outcomes and performance indicators were calculated for abnormalities detected by screening mammography only.
The abnormal recall rate was 9.5% for first screens and 4.6% for subsequent screens, and the cancer detection rate per 1000 women screened was 6.9 for first screens and 3.8 for subsequent screens. The positive predictive value (i.e., the proportion of women who tested positive by mammography who were found to have breast cancer on screen-initiated diagnostic work-up) increased from 7.2% at the first screen to 8.2% at subsequent screens. Estimated participation rates within organized programs varied from 10.6% to 54.2%, depending on the province.
For 1996, organized breast cancer screening programs met or exceeded many of the interim measures used in international programs. It is possible to translate the benefits of breast cancer screening by mammography, as demonstrated in randomized trials, into population-based community programs. Screening mammography through organized programs should increase to allow more comprehensive monitoring in Canada.
随机试验结果表明,乳腺钼靶筛查可使50 - 69岁女性的乳腺癌死亡率降低多达40%。鉴于这些结果,到1998年,包括加拿大在内的22个国家已建立了基于人群的有组织筛查项目。本文介绍了1996年加拿大7个省级组织的乳腺癌筛查项目中乳腺钼靶筛查的结果。
根据提交至加拿大乳腺癌筛查数据库的数据,计算了乳腺钼靶筛查的中期绩效指标。数据集由7个省级项目的数据组成,仅限于50 - 69岁女性的钼靶筛查(n = 203,303)。仅针对通过乳腺钼靶筛查检测出的异常情况计算筛查结果和绩效指标。
首次筛查的异常召回率为9.5%,后续筛查为4.6%;每1000名接受筛查的女性中,首次筛查的癌症检出率为6.9,后续筛查为3.8。阳性预测值(即通过钼靶检查呈阳性的女性中,在筛查启动的诊断检查中被发现患有乳腺癌的比例)从首次筛查时的7.2%升至后续筛查时的8.2%。有组织项目中的估计参与率因省份而异,从10.6%至54.2%不等。
1996年,有组织的乳腺癌筛查项目达到或超过了国际项目中使用的许多中期指标。如随机试验所示,乳腺钼靶筛查的益处有可能转化为基于人群的社区项目。通过有组织项目进行的乳腺钼靶筛查应增加,以便在加拿大进行更全面的监测。